JP2000512980A5 - - Google Patents

Download PDF

Info

Publication number
JP2000512980A5
JP2000512980A5 JP1998500803A JP50080398A JP2000512980A5 JP 2000512980 A5 JP2000512980 A5 JP 2000512980A5 JP 1998500803 A JP1998500803 A JP 1998500803A JP 50080398 A JP50080398 A JP 50080398A JP 2000512980 A5 JP2000512980 A5 JP 2000512980A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998500803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000512980A (ja
Filing date
Publication date
Priority claimed from US08/659,206 external-priority patent/US5922685A/en
Application filed filed Critical
Publication of JP2000512980A publication Critical patent/JP2000512980A/ja
Publication of JP2000512980A5 publication Critical patent/JP2000512980A5/ja
Ceased legal-status Critical Current

Links

JP10500803A 1996-06-05 1997-06-04 腫瘍のil―12遺伝子治療 Ceased JP2000512980A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/659,206 1996-06-05
US08/659,206 US5922685A (en) 1996-06-05 1996-06-05 IL-12 gene therapy of tumors
PCT/US1997/009591 WO1997046263A1 (en) 1996-06-05 1997-06-04 Il-12 gene therapy of tumors

Publications (2)

Publication Number Publication Date
JP2000512980A JP2000512980A (ja) 2000-10-03
JP2000512980A5 true JP2000512980A5 (enExample) 2005-01-13

Family

ID=24644498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10500803A Ceased JP2000512980A (ja) 1996-06-05 1997-06-04 腫瘍のil―12遺伝子治療

Country Status (6)

Country Link
US (1) US5922685A (enExample)
EP (1) EP0963207B1 (enExample)
JP (1) JP2000512980A (enExample)
DE (1) DE69735643T2 (enExample)
ES (1) ES2262180T3 (enExample)
WO (1) WO1997046263A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
AU761520B2 (en) * 1998-09-15 2003-06-05 Genetics Institute, Llc Treatment of Kaposi's Sarcoma with IL-12
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK1842002A3 (en) * 1999-08-09 2003-09-11 Lexigen Pharm Corp A fusion protein, a multi-function protein complex, a multi-function fusion protein, a nucleic acid, a cell, their use, method for preparing a fusion protein and method of targeting cytokines
US20030190305A1 (en) * 1999-09-15 2003-10-09 Wyeth And National Institutes Of Health Treatment of Kaposi's sarcoma with IL-12
US6626871B1 (en) 1999-10-11 2003-09-30 Felton International, Inc. Method and apparatus for removing cap from medical device
US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
AU778826B2 (en) * 1999-10-29 2004-12-23 Anges Mg, Inc. Gene therapy for diabetic ischemic disease
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
US20040213798A1 (en) * 2000-06-08 2004-10-28 Powderject Vaccines, Inc. Spray-dried alum compositions
MXPA02012734A (es) * 2000-06-29 2003-04-25 Merck Patent Gmbh Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
PT1366067E (pt) * 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
PL205352B1 (pl) * 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
CA2349506C (en) * 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
US7833754B2 (en) * 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
BRPI0818287A2 (pt) * 2007-10-08 2015-11-03 Intrexon Corp células dendríticas manipuladas e usos para o tratamento do câncer.
KR101361416B1 (ko) 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
AU2010241864B2 (en) * 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20110014228A1 (en) * 2009-06-15 2011-01-20 New York University Il23 modified viral vector for recombinant vaccines and tumor treatment
KR20220159479A (ko) 2016-05-18 2022-12-02 모더나티엑스, 인크. 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5015580A (en) * 1987-07-29 1991-05-14 Agracetus Particle-mediated transformation of soybean plants and lines
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
JP3221683B2 (ja) * 1994-01-21 2001-10-22 パウダージェクト ヴァクシンズ, インコーポレイテッド ガス駆動型遺伝子搬入装置
AU4908197A (en) * 1996-10-18 1998-05-15 Valentis, Inc. Gene expression and delivery systems and uses

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000506430A5 (enExample)
JP2000501771A5 (enExample)
JP2000510733A5 (enExample)
JP2001505109A5 (enExample)
JP2000506627A5 (enExample)
JP2000501599A5 (enExample)
JP2001505363A5 (enExample)
JP2002514195A5 (enExample)
JP2000516485A5 (enExample)
JP2000510735A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2001500952A5 (enExample)
JP2001500372A5 (enExample)
JP2001522482A5 (enExample)
JP2000510181A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000505485A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000512980A5 (enExample)